TY - JOUR
T1 - Assessment of determining factors for severity of NeoCOVIDiabetes in India
T2 - A pan India multicentric retrospective study
AU - Maheshwari, Anuj
AU - Hasnani, Dhruvi
AU - Bhattacharya, Meenakshi
AU - Mukhyaprana Prabhu, M.
AU - Saxena, Divya
AU - Khandelwal, Bidita
AU - Nawal, C. L.
AU - Makkar, Brij Mohan
AU - Ansari, Sajid
AU - Chawla, Prahlad
AU - Agrawal, Prabhat
AU - Saxena, Ashish
AU - Verma, Narsingh
AU - Saboo, Banshi
AU - Chavda, Vipul
AU - Singh, Uday Pratap
AU - Arora, Vanshika
N1 - Funding Information:
MEDEVA (https://medeva.io), as an Artificial Intelligence and Machine Learning enabled EMR platform, was the implementation, research, and insight partners for the study. Kartik V, Siddhartha Nautiyal, Rama Regulla, Dr. Venugopala Rao, Sandhya T, and Swapna C, as a special mention, who contributed significantly for training, data analytics and manuscript editing processes of the study.
Publisher Copyright:
© 2022 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC)
PY - 2023/1
Y1 - 2023/1
N2 - Background and aims: There is a bidirectional relationship between COVID-19 and diabetes. The primary objective of this study was to estimate the prevalence of patients newly detected to have diabetes (NDD) who recovered from COVID-19 in India whilst comparing NDD with patients without diabetes (ND) and those who have known to have diabetes (KD) in terms of glycemic status pre- and post-COVID with disease severity. Materials & methodology: There were 2212 participants enrolled from 15 sites, with 1630 active participants after the respective execution of selection criteria. Data collection was done using a specialized Case Record Form (CRF). Planned statistical analysis and descriptive statistics were concluded for significance between patient groups on various parameters. Result: The differences in age between the study groups were statistically significant. The average blood glucose at COVID-19 onset was significantly higher in KD than in NDD. Significantly more proportion of NDD (83%) had been hospitalized for COVID management when compared to KD (45%) and ND (55%). The NDD group received higher doses of steroids than the other two groups. On average, patients in the NDD group who received at least one vaccination (one dose or two doses) had a higher High-Resolution Computed Tomography (HRCT) score. Patients who had not been vaccinated in ND and KD groups experienced a higher HRCT score. Conclusion: Prospective metabolism studies in post-acute COVID-19 will be required to understand the etiology, prognosis, and treatment opportunities.
AB - Background and aims: There is a bidirectional relationship between COVID-19 and diabetes. The primary objective of this study was to estimate the prevalence of patients newly detected to have diabetes (NDD) who recovered from COVID-19 in India whilst comparing NDD with patients without diabetes (ND) and those who have known to have diabetes (KD) in terms of glycemic status pre- and post-COVID with disease severity. Materials & methodology: There were 2212 participants enrolled from 15 sites, with 1630 active participants after the respective execution of selection criteria. Data collection was done using a specialized Case Record Form (CRF). Planned statistical analysis and descriptive statistics were concluded for significance between patient groups on various parameters. Result: The differences in age between the study groups were statistically significant. The average blood glucose at COVID-19 onset was significantly higher in KD than in NDD. Significantly more proportion of NDD (83%) had been hospitalized for COVID management when compared to KD (45%) and ND (55%). The NDD group received higher doses of steroids than the other two groups. On average, patients in the NDD group who received at least one vaccination (one dose or two doses) had a higher High-Resolution Computed Tomography (HRCT) score. Patients who had not been vaccinated in ND and KD groups experienced a higher HRCT score. Conclusion: Prospective metabolism studies in post-acute COVID-19 will be required to understand the etiology, prognosis, and treatment opportunities.
UR - http://www.scopus.com/inward/record.url?scp=85144930970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144930970&partnerID=8YFLogxK
U2 - 10.1016/j.dsx.2022.102692
DO - 10.1016/j.dsx.2022.102692
M3 - Article
AN - SCOPUS:85144930970
SN - 1871-4021
VL - 17
JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
IS - 1
M1 - 102692
ER -
